Carol Suh is the co-founder and senior vice president, strategy of Neumora and a partner with ARCH Venture Partners. A stem cell biologist by training, Carol combines her scientific expertise with the business side of biotech.
At ARCH Venture Partners, Carol is involved in company creation and helped build Sana Biotechnology, Autobahn Therapeutics and Boundless Bio across the fields of cell and gene therapy, neuroscience and oncology. Prior to ARCH, Carol helped launch Magenta Therapeutics, a biotech company transforming the way bone marrow stem cell transplants are performed. Previously, she was a consultant at Trinity Partners, where she worked with a wide range of biotech and pharma companies on corporate strategy, market research and business development.
Carol began her career in R&D strategy with GlaxoSmithKline’s Regenerative Medicine group. For her work, she was recognized on the 2015 Forbes 30 Under 30 list in Healthcare.
Carol holds an an MBA from Stanford Graduate School of Business and an A.B. in molecular cellular biology from Harvard University, where she trained under Dr. David Scadden at the Harvard Stem Cell Institute. She also holds an M.Phil. from Yale University and was awarded the National Science Foundation Graduate Research Fellowship for her work in stem cell biology.